Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Oligometastatic Gastrointestinal Cancer 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1BRAF V600E-mutated /MSS Metastatic Colorectal Cancer 1Advanced Tumors 1Advanced Solid Tumors 1Advanced Gastric Cancer 1Advanced Cervical Cancer 1

Interventions

Etoposide 5Carboplatin 3Cisplatin 2oblimersen 1obinutuzumab 1gossypol acetic acid 1camrelizumab 1apatinib 1NVP-BKM120 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Extensive Stage Small Cell Lung Cancer × camrelizumab × Clear all
NCT05001412 2021-08-12

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Guangzhou Institute of Respiratory Disease

Phase 1 Unknown
36 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡